Literature DB >> 20713046

Sleep alterations in an environmental neurotoxin-induced model of parkinsonism.

Kimberly A McDowell1, Maria M Hadjimarkou, Shaun Viechweg, Avigail E Rose, Sarah M Clark, Paul J Yarowsky, Jessica A Mong.   

Abstract

Parkinson's disease (PD) is classically defined as a motor disorder resulting from decreased dopamine production in the basal ganglia circuit. In an attempt to better diagnose and treat PD before the onset of severe motor dysfunction, recent attention has focused on the early, non-motor symptoms, which include but are not limited to sleep disorders such as excessive daytime sleepiness (EDS) and REM behavioral disorder (RBD). However, few animal models have been able to replicate both the motor and non-motor symptoms of PD. Here, we present a progressive rat model of parkinsonism that displays disturbances in sleep/wake patterns. Epidemiological studies elucidated a link between the Guamanian variant of Amyotrophic Lateral Sclerosis/Parkinsonism Dementia Complex (ALS/PDC) and the consumption of flour made from the washed seeds of the plant Cycas micronesica (cycad). Our study examined the effects of prolonged cycad consumption on sleep/wake activity in male, Sprague-Dawley rats. Cycad-fed rats exhibited an increase in length and/or number of bouts of rapid eye movement (REM) sleep and Non-REM (NREM) sleep at the expense of wakefulness during the active period when compared to control rats. This hypersomnolent behavior suggests an inability to maintain arousal. In addition, cycad-fed rats had significantly fewer orexin cells in the hypothalamus. Our results reveal a novel rodent model of parkinsonism that includes an EDS-like syndrome that may be associated with a dysregulation of orexin neurons. Further characterization of this early, non-motor symptom, may provide potential therapeutic interventions in the treatment of PD.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713046      PMCID: PMC2955757          DOI: 10.1016/j.expneurol.2010.08.005

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  25 in total

1.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

2.  Environmental neurotoxin-induced progressive model of parkinsonism in rats.

Authors:  Wei-Bin Shen; Kimberly A McDowell; Aubrey A Siebert; Sarah M Clark; Natalie V Dugger; Kimberly M Valentino; H A Jinnah; Carole Sztalryd; Paul S Fishman; Christopher A Shaw; M Samir Jafri; Paul J Yarowsky
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

Review 3.  Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis.

Authors:  Takeshi Sakurai
Journal:  Sleep Med Rev       Date:  2005-08       Impact factor: 11.609

4.  Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.

Authors:  Quentin Barraud; Virginie Lambrecq; Claude Forni; Steve McGuire; Michael Hill; Bernard Bioulac; Emmanuel Balzamo; Erwan Bezard; François Tison; Imad Ghorayeb
Journal:  Exp Neurol       Date:  2009-07-25       Impact factor: 5.330

5.  Lewy bodies in the lateral hypothalamus: do they imply neuronal loss?

Authors:  H P Kremer; G T Bots
Journal:  Mov Disord       Date:  1993-07       Impact factor: 10.338

Review 6.  Disorders of excessive daytime sleepiness--an update.

Authors:  B El-Ad; A D Korczyn
Journal:  J Neurol Sci       Date:  1998-01-08       Impact factor: 3.181

7.  The hypothalamus in Parkinson disease.

Authors:  J W Langston; L S Forno
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

8.  Interleukin-1beta mediates sleep alteration in rats with rotenone-induced parkinsonism.

Authors:  Pei-Lu Yi; Chon-Haw Tsai; Ming-Kuei Lu; Hsu-Jan Liu; Ya-Chu Chen; Fang-Chia Chang
Journal:  Sleep       Date:  2007-04       Impact factor: 5.849

Review 9.  Sleep disturbances and Parkinson's disease.

Authors:  Joseph H Friedman; Richard P Millman
Journal:  CNS Spectr       Date:  2008-03       Impact factor: 3.790

10.  Hypocretin (orexin) cell loss in Parkinson's disease.

Authors:  Thomas C Thannickal; Yuan-Yang Lai; Jerome M Siegel
Journal:  Brain       Date:  2007-05-09       Impact factor: 13.501

View more
  10 in total

1.  In utero exposure to valproic acid changes sleep in juvenile rats: a model for sleep disturbances in autism.

Authors:  Danielle M Cusmano; Jessica A Mong
Journal:  Sleep       Date:  2014-09-01       Impact factor: 5.849

Review 2.  Animal models of Parkinson's disease: a gateway to therapeutics?

Authors:  Weidong Le; Pavani Sayana; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Sleep disturbances in Alzheimer's and Parkinson's diseases.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2012-05-03       Impact factor: 3.843

Review 4.  Animal models of the non-motor features of Parkinson's disease.

Authors:  Kimberly McDowell; Marie-Françoise Chesselet
Journal:  Neurobiol Dis       Date:  2012-01-03       Impact factor: 5.996

5.  Rethinking cycad metabolite research.

Authors:  Laura R Snyder; Thomas E Marler
Journal:  Commun Integr Biol       Date:  2011-01

6.  Gonadal steroid modulation of sleep and wakefulness in male and female rats is sexually differentiated and neonatally organized by steroid exposure.

Authors:  Danielle M Cusmano; Maria M Hadjimarkou; Jessica A Mong
Journal:  Endocrinology       Date:  2013-12-20       Impact factor: 4.736

7.  Polysomnographic Features of Sleep Disturbances and REM Sleep Behavior Disorder in the Unilateral 6-OHDA Lesioned Hemiparkinsonian Rat.

Authors:  Quynh Vo; Timothy P Gilmour; Kala Venkiteswaran; Jidong Fang; Thyagarajan Subramanian
Journal:  Parkinsons Dis       Date:  2014-12-25

Review 8.  The BSSG rat model of Parkinson's disease: progressing towards a valid, predictive model of disease.

Authors:  Jackalina M Van Kampen; Harold A Robertson
Journal:  EPMA J       Date:  2017-09-04       Impact factor: 6.543

9.  Acute levodopa dosing around-the-clock ameliorates REM sleep without atonia in hemiparkinsonian rats.

Authors:  Vishakh Iyer; Quynh Vo; Anthony Mell; Siven Chinniah; Ashley Zenerovitz; Kala Venkiteswaran; Allen R Kunselman; Jidong Fang; Thyagarajan Subramanian
Journal:  NPJ Parkinsons Dis       Date:  2019-11-29

Review 10.  Sleep and circadian rhythms in Parkinson's disease and preclinical models.

Authors:  Jeremy Hunt; Elizabeth J Coulson; Rajendram Rajnarayanan; Henrik Oster; Aleksandar Videnovic; Oliver Rawashdeh
Journal:  Mol Neurodegener       Date:  2022-01-09       Impact factor: 14.195

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.